Biocept rolls out liquid biopsy test for colorectal cancer; Sequenom struggles in Q2;

> Liquid biopsy outfit Biocept ($BIOC) launched its first diagnostic test for colorectal cancer. More

> Quanterix and Beth Israel Deaconess Medical Center are touting results from a new study showing the efficacy of Quanterix's Simoa technology in rapidly diagnosing C. difficile infections in stool samples. Statement

> Sequenom ($SQNM) stumbled during its second quarter, announcing revenues of $32.8 million--an 18% drop compared to the same quarter last year. More

> The Centers for Disease Control and Prevention (CDC) is funneling about $2.3 million in fiscal 2016 toward sequencing and bioinformatics technologies to fight infectious disease. Story (reg. req.)

> Exosome Diagnostics cut the ribbon on its Cambridge, MA-based CLIA-certified lab. Statement

And Finally… A new, video game-like tool for detecting early signs of Alzheimer's snagged marketing approval from the FDA. Story